These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29090083)

  • 1. Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.
    Shohdy KS; Lasheen S; Kassem L; Abdel-Rahman O
    Ther Adv Drug Saf; 2017 Nov; 8(11):337-347. PubMed ID: 29090083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Bachelot T
    Breast Cancer; 2018 Jan; 25(1):17-27. PubMed ID: 29147869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis.
    Long Q; Li X; Wu G; Zhang J; Li H
    Ann Palliat Med; 2021 Jun; 10(6):6556-6563. PubMed ID: 34237967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Lasheen S; Shohdy KS; Kassem L; Abdel-Rahman O
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):851-856. PubMed ID: 28699811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
    Sun W; Li J; Zhang Z; Su X
    J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
    Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis.
    Huo GW; Zhu FY; Zuo R; Song Y; Chen WD; Chen WM; Zhang HM; Jia SS; Chen P
    Transl Cancer Res; 2021 Jul; 10(7):3389-3403. PubMed ID: 35116644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1229-42. PubMed ID: 25119858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
    Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
    Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.
    Jiang N; Song XW; Lin JJ; Wang ZY; Zhang BN; Li A; Yan RY; Yan HF; Fu XY; Zhou JL; Li CL; Cui Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1111-1119. PubMed ID: 28766379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Ma Z; Sun X; Feng X; An Z
    Breast; 2022 Apr; 62():162-169. PubMed ID: 35219113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
    Yang W; Men P; Xue H; Jiang M; Luo Q
    Front Oncol; 2020; 10():197. PubMed ID: 32211312
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
    Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Gastrointestinal Events During Lapatinib Therapy: A Meta-Analysis From 12,402 Patients With Cancer.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2018; 25(4):e412-e422. PubMed ID: 26938760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.